Lu-177-labeled Payloaded Liposome for SPECT/Optical Dual-modality Imaging and Combined Radio- and Chemotherapy in LLC Mice Model

Di Fan,Jiyun Shi,Zhai Luoping,Hannan Gao,Xin Zhang,Kai Wang,Zhen Qiao,Qian Chen,Xiaobin Zhao,Lin Ai,Fan Wang

2018-01-01

Journal of Nuclear Medicine

Abstract:1134 Objectives: Liposome, as a FDA proved nano-sized drug carrier material with excellent biodegradability and biocompatibility, has been extensively used in tumor chemotherapy. Liposomes not only can encapsulate small drug molecules or signaling molecules, but also can be easily and conveniently modified externally, which is an unique advantage for developing multifunctional and theranostic nanoparticle probes. Liposomes have been radiolabeled and applied mostly for tumor detection, but very rarely for radiotherapy. Herein, 177Lu-labeled DiR-encapsulated liposome was evaluated for SPECT/Optical dual-modality imaging and biodistribution in Lewis lung cancer (LLC) xenografts. Furthermore, the therapeutic efficacy of 177Lu-labeled Dox-encapsulated liposome for combination radio-chemotherapy was firstly assessed in LLC xenografts. Methods: Biodistribution, SPECT/Optical dual-modality imaging and maximum tolerated dose (MTD) studies of 177Lu-Liposome were performed. The radiotherapy studies were begun when the tumor reached 50~80 mm3 and were compared with liposome encapsulated Doxorubicin or in combination. The liposome encapsulated Doxorubicin was given once every three days for three times totally. Tumor size and body weight were monitored every other day. When the tumor volume reached 1500 mm3 or more than 20% of the weight loss, the experiment was concluded. Results: 177Lu-Liposome are slowly cleared from the blood and at 24 h post-injection, tumor uptake reached the highest (7.55 ± 3.85%ID/g); until 72 h post-injection, the tumor is still maintaining a high uptake (5.02 ± 2.75%ID/g). The tumors were clearly visualized by the SPECT/Optical imaging. Compared with liposome encapsulated Doxorubicin alone, the 177Lu-liposome or the combination of 177Lu-liposome with doxorubicin has further notably inhibited tumor growth. From the fifth day post-treatment, the combination therapy of 177Lu-Dox-liposome has an enhanced inhibition of tumor growth than that of Dox-liposome or 177Lu-liposome, and this advantage has been maintained until the experiment was concluded. Conclusions: The 177Lu-radiolabeled payloaded liposome was prepared as a multifunctional nanoprobe. Passive targeted therapy of 177Lu-liposome is effective in LLC tumor model. 177Lu-liposome radiotherapy alone or combination with Dox-liposome, can remarkably suppress the tumor growth in LLC tumor model. Development of the multimodality imaging nanoprobe and its potential for the diagnosis and treatment is in progress.